The company secured a Level A outcome after a comprehensive audit of its internal procedures, ranging from donor screening to final product storage. This certification validates the firm’s current infrastructure and provides a formal framework for its planned expansion into new clinical markets. By meeting these requirements, the organization can now leverage its status to secure partnerships with healthcare providers who mandate AATB-verified supply chains for tissue restoration.

Jaime Leija, president of BioLab Holdings, described the milestone as a foundational element for the company’s growth strategy. Vice president of quality Christy Norman noted that the process required an overhaul of department-wide workflows to align with the association's rigorous safety expectations. This accreditation serves as a strategic asset for BioLab as it seeks to commercialize new technologies and increase its footprint within the medical technology sector.